Icatibant Newbury

Icatibant, the active ingredient in Icatibant Newbury, is a bradykinin B2 receptor antagonist presented as a solution for injection for subcutaneous use. The formulation is designed for rapid subcutaneous administration to address swelling episodes in acute hereditary angioedema attacks.

GNH USA supplies Icatibant Newbury as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, transplant centres, oncology centres and clinics worldwide, with a focus on quality assurance and regulatory compliance. The company provides cold‑chain logistics where required and supports import documentation for global markets.

Icatibant is used to treat conditions mediated by excessive bradykinin activity, primarily hereditary angioedema.

- Acute attacks of hereditary angioedema (C1‑inhibitor deficiency): provides rapid relief of swelling and pain associated with HAE episodes.

Icatibant may cause a range of adverse reactions following subcutaneous administration.

Common Side Effects: - Injection site pain: discomfort at the injection site. - Erythema: redness around the injection area. - Nausea: feeling of sickness or urge to vomit. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure. - Angioedema: swelling of deeper skin layers or mucosa. - Thrombocytopenia: low platelet count that may increase bleeding risk.

Before using Icatibant, consider the following safety measures.

- Pregnancy: safety not established; avoid unless benefit outweighs risk. - Breastfeeding: unknown effects; weigh potential risks before use. - Renal impairment: use with caution and monitor renal function. - Concomitant ACE inhibitors: may increase bradykinin levels; monitor closely. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that affect bradykinin pathways or cardiovascular function.

Major Interactions (Avoid): - ACE inhibitors: may potentiate bradykinin‑mediated effects. - Neprilysin inhibitors: increase bradykinin levels. - Estrogen‑containing therapies: can raise bradykinin production.

Moderate Interactions (Monitor Closely): - NSAIDs: may exacerbate gastrointestinal irritation. - Diuretics: could affect blood pressure stability. - Antihypertensive agents: monitor for additive hypotensive effects.